CD276 and neoplasm: After showing tumor regression in preclinical mouse xenograft models of osteosarcoma and Ewing sarcoma (83), a phase I clinical trial (NCT04483778) using B7-H3 CAR-T cells is currently recruiting patients with B7-H3 expressing tumors.